Therapeutic options for pulmonary arterial hypertension (PAH) have increased over the last
decades. The advent of pharmacological therapies targeting the prostacyclin, endothelin …

Pulmonary arterial hypertension (PAH) describes a group of conditions with a common
hemodynamic phenotype of increased pulmonary artery pressure, driven by progressive …

Sex differences in the anatomy and physiology of the respiratory system have been widely
reported. These intrinsic sex differences have also been shown to modulate the …

Pulmonary hypertension (PH) encompasses a syndrome of diseases that are characterized
by elevated pulmonary artery pressure and pulmonary vascular remodeling and that …

Obesity is a prevalent global public health issue characterized by excess body fat. Adipose
tissue is now recognized as an important endocrine organ releasing an abundance of …

Background: Pulmonary arterial hypertension (PAH) is a heterogeneous disorder with high
mortality. Methods: We conducted a comprehensive study of plasma metabolites using …

Pulmonary hypertension is a progressive and often fatal cardiopulmonary condition
characterised by increased pulmonary arterial pressure, structural changes in the pulmonary …

Right ventricle (RV) dysfunction is the strongest predictor of mortality in pulmonary arterial
hypertension (PAH), but, at present, there are no therapies directly targeting the failing RV …

Background: Excessive proliferation and apoptosis resistance of pulmonary artery smooth
muscle cells (PASMCs) are key mechanisms of pulmonary arterial hypertension (PAH) …

Rationale: The aromatase inhibitor anastrozole blocks the conversion of androgens to
estrogen and blunts pulmonary hypertension in animals, but its efficacy in treating patients …